Compare Neurocrine Biosciences Inc (NBIX) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Vale SA — how do they compare? Neurocrine Biosciences Inc trades at $142.36 (market cap $14.36B), while Vale SA trades at $13.63 (market cap $57.32B). The key difference: Vale SA is far larger — about 4× Neurocrine Biosciences Inc's market cap, and Vale SA pays a 8.87% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Vale SA for 109 Days on average.
| NBIX | VALE | |
|---|---|---|
Market Cap | $14.36B | $57.32B |
Volume | 1,237,180 | 27,996,846 |
Sector | Health | Basic Materials |
52-Week High | $185.50 | $17.82 |
52-Week Low | $123.10 | $10.75 |
Typical Hold Time | 23 Days | 109 Days |
Enterprise Value | $14.37B | $73.56B |
Dividend Yield | — | 8.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
VALE trades at $13.62, near recent lows, with a bearish technical outlook and mixed sentiment. The stock has missed earnings expectations in recent quarters, with Q3 2026 EPS expected at $0.4212. Revenue has declined from $43.8B in 2022 to $38.4B in 2025, though 2026 is projected at $41.2B. Net income margin compressed to 5.11% in 2025. Analyst consensus is a 'Hold' with a $16.21 price target, indicating modest upside potential from current levels.
VALE faces headwinds from cyclical commodity exposure and cost inflation, but its base metals segment shows growth. Investment appeal hinges on iron ore price stability and execution on cost controls. Risks include regulatory challenges in Brazil and volatile raw material markets. The stock offers a dividend yield but requires careful monitoring of earnings trajectory and macroeconomic factors affecting mining sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
